Vendor Intelligence Report: Wuhan HongyouJie HYJ

Published 2 Jul 2026. 17-page investigative report on who is behind Wuhan HongyouJie HYJ: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, HYJ shows 3 pass and 1 fail, for a 75% overall pass rate. The record is narrow: every Finnrick sample in this dossier is Tirzepatide. HYJ therefore looks capable of delivering acceptable Tirzepatide batches, but the failed sample keeps it in conditional, moderate-risk territory rather than a high-confidence recommendation. Stricter fill-focused grading also changes the comfort read.

Beyond the assays, HYJ’s paper trail is thinner than its storefront suggests. WHOIS and archive records place the peptide-facing web operation much later than the site’s legacy-history signal, while a business-platform profile points to a different province than HYJ’s own contact page. Chinese corporate registry verification remains unresolved, so the entity identity is coherent but the accountable operating footprint is not fully anchored.

The strongest human link is a sales identity: Mia Su on a business marketplace and Mia51888 in the MESO-RX vendor thread appear tied to the same HYJ channel. That forum presence is a real-market signal, not a guarantee; MESO-RX and UK-Muscle material show delayed tracking, shipping interruptions, wrong-order/service concerns, and a messaging-app authentication problem flagged by a supplier platform. The promotion scan did not surface coupon-code promoters or an indexed referral network on the scanned X/web surfaces.

For buyers already considering HYJ, the practical read is product-specific. Tirzepatide is a conditional option only with batch-specific documentation and independent verification where possible; other catalog items should be treated as untested by Finnrick. The full report lays out the records and exhibits behind that summary.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data, per-product detail, and methodology-divergence chart for the single tested product
  • WHOIS, Wayback, and site-footer timeline comparing verified web age with legacy-history signals
  • Website, Global Sources, and Tracxn identity/address review, including unresolved Chinese registry status
  • UEEShop storefront and infrastructure review, including the associated platform URL
  • Mia Su / Mia51888 sales-channel mapping across Global Sources and MESO-RX
  • MESO-RX and UK-Muscle fulfilment excerpts plus channel-verification precautions

Risk assessment

  • Misleading operational-history risk — high: hytmy.com was registered on 2024-11-11 while the site carries 2005–2015/MySite Ltd history signals; no Wayback or Chinese-registry evidence verified a legacy operation.
  • Address and accountability discrepancy risk — high: Website lists 451 Heping Avenue in Wuhan/Hubei, while Global Sources lists xingtaineiqiuxuan, Hebei; Chinese corporate registry verification remains unresolved.
  • Product quality-control risk — Tirzepatide — medium: Finnrick records only Tirzepatide for HYJ: 4 tests, 3 pass/1 fail, 78.23%, making it a usable but not high-confidence choice.
  • Fulfilment and communications risk — medium: MESO-RX/UK-Muscle threads document shipping delays, tracking/order issues, and Global Sources warns against WhatsApp/WeChat contact veracity.